Fondazione FORT

La Fondazione Ricerca Traslazionale (FoRT), si propone di svolgere attività scientifica e di ricerca nel settore biomedico con particolare, ma non esclusivo, interesse alla ricerca traslazionale applicata in campo oncologico, pre-clinico e clinico.

"PF‐06463922 for crizotinib pretreated ROS1 positive nonsmall‐cell lung cancer: a phase II Trial (PFROST)"

"Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or MET exon 14 mutation or ROS1 translocation (METROS)"

"(Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, parallel, non comparative phase II trial of nivolumab plus ipilimumab versus platinum-based chemotherapy plus nivolumab in chemonaive metastatic or recurrent Squamous-Cell Lung Cancer (SqLC) "

"Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC)"

"Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation"

"Crizotinib in ALK rearranged non-small-cell lung cancer: a retrospective study"

"Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients"

"Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non-Small-Cell Lung Cancer patients receiving concomitant steroids"

"Database patologie polmonari"


"Prospective study evaluating the development of anti-checkpoint inhibitor antibodies in patients treated with immunotherapy"

"A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations"

"NTRK 1,2,3 rearrangements in patients with solid tumors"


"A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progressing after first-line chemo-immunotherapy (Combi-TED)"

"Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab"

"A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and Expansion Phase in Subjects with Advanced EGFR mutated Non-Small Cell Lung Cancer who are resistant to EGFR tyrosine kinase inhibitors"

"Observational study to analyse the expression of immunological BIOmarkers, their association with patient outcome and their association to CHECKpoint inhibitor therapy clinical response in cancer patients"